Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
BioMarin Pharmaceutical
American company
Nothing else this week.
Related events
- BioMarin Pharmaceutical and XTL Biopharmaceuticals are identified as healthcare companies competing for investment.
- Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
- Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
- Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.
Coverage
Newest first; wire copies grouped- Insider MonkeyLeerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top most undervalued biotech stocks to buy now.
- Insider MonkeyLeerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to invest in now. On July